The utility of onyx for preoperative embolization of cranial and spinal tumors.


Journal Article

OBJECTIVE: To assess the utility, technical factors, and complications associated with the use of Onyx (Micro Therapeutics, Inc., Irvine, CA) for preoperative embolization of cranial and spinal tumors. METHODS: We reviewed a prospectively accumulated database for patients in whom Onyx was used for preoperative embolization of cranial and spinal tumors over a 19-month period. The patients' demographic characteristics, tumor type and location, embolic agents used, arteries catheterized, and associated complications were assessed. Specific attention was focused on technical factors associated with the use of Onyx that differed from the use of other commonly used embolic materials. RESULTS: Ten patients (four female and six male; age range, 11-60 yr) underwent preoperative embolization with Onyx before cranial or spinal tumor resection. Tumors included three juvenile nasal angiofibromas, two meningiomas, two hemangioblastomas, two metastases (renal cell and thyroid), and one giant cell tumor. Onyx embolization was performed in 43 vessels over 11 treatment sessions. There were no complications related to the embolization procedures. Deep penetration of the embolic agent into the tumor was documented through preoperative imaging or surgical pathological specimens. CONCLUSION: Preoperative embolization of cranial and spinal tumors can be performed safely. Specific technical advantages of Onyx included deep penetration of lesions producing extensive tumor infarction, the ability to embolize extensive portions of the tumors through fewer arterial catheterizations, and the safety of catheter withdrawal despite often substantial reflux along the embolic catheter.

Full Text

Duke Authors

Cited Authors

  • Gore, P; Theodore, N; Brasiliense, L; Kim, LJ; Garrett, M; Nakaji, P; Gonzalez, LF; McDougall, CG; Albuquerque, FC

Published Date

  • June 2008

Published In

Volume / Issue

  • 62 / 6

Start / End Page

  • 1204 - 1211

PubMed ID

  • 18824987

Pubmed Central ID

  • 18824987

Electronic International Standard Serial Number (EISSN)

  • 1524-4040

Digital Object Identifier (DOI)

  • 10.1227/


  • eng

Conference Location

  • United States